|
For immediate release
March 27, 2008
EnzySurge, maker of DermaStream™, establishes a U.S. office
in the Virginia Biosciences Commercialization Center
Richmond, Va. – The Virginia Biosciences Commercialization Center recently announced the newest company to establish their U.S. office at the Virginia BioTechnology Research Park as a member of the VBCC program — EnzySurge, an Israeli bioscience company focused on chronic wound management.
“EnzySurge has developed DermaStream™ based on its proprietary Continuous Streaming Therapy™ (CST) technology. DermaStream is a comprehensive yet versatile treatment for hard-to-heal chronic wounds throughout the debridement, regeneration and closure phases, designed for hospitals, clinics and home treatment” stated Donna Edmonds, executive director of the VBCC. “We’re very excited to support the introduction of this innovative product line to the U.S. market.” Pressure, venous and diabetic wounds are an increasing problem in the United States, with more than 6 million cases reported annually. Each year, more than 2.3 million Americans are treated for diabetes-related skin ulcers and more than 100,000 amputations are performed on diabetic patients due to non-healing wounds.
Treatment of chronic wounds is a costly, long and multistep process that often requires hospitalization, and it is extremely uncomfortable for the patient. The process involves debriding the wound, surgically removing unhealthy tissue, flushing the wound with anti-microbial products and keeping the open wound clear of infection to promote tissue regeneration and hopefully lead to wound closure.
The DermaStream device continuously streams fresh, highly active solutions in an isolated, optimally receptive and bacteria-controlled wound environment, and thereby provides faster, more effective and comprehensive chronic wound treatment — from wound debridement, through regeneration to closure.
“We’re dedicated to developing innovative solutions that expedite wound healing and improve patients’ quality of lives,” stated Amir Shiner, CEO of EnzySurge. “The VBCC program brings us closer to getting a much needed medical tool in the hands of the clinicians who can use them.”
About the Park
The Virginia BioTechnology Research Park is currently home to a unique mix of more than 55 public and private bioscience companies, research institutes affiliated with the VCU Medical Center and major state and national medical laboratories. These companies are housed in nine buildings totaling more than 1.1 million square feet of space, representing an employee base that exceeds 2,000. The VBDC is the Virginia BioTechnology Research Park’s business assistance program located in its 27,000-square-foot incubator. Since opening in 1995, 63 companies have started in the Park’s incubator facility; 31 of which have graduated into larger spaces in the Park or greater Richmond community. The Park’s Commercialization Center has been created to take incubator graduates through commercialization to M&A or IPO, giving the Park’s tenants full-scale business assistance.The Commercialization Center is now the home of eight companies from the Israeli life science community and continues to expand its resource base. It has created alliances with leading incubators in Israel. To date, the Park has graduated three companies that are now publicly traded.
About EnzySurge
EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge’s patented and FDA-cleared DermaStream™ is an innovative wound care platform which, together with a set of advanced bio-active solutions, forms the basis for the new and unique wound treatment modality — Continuous Streaming Therapy™. DermaStream enables a new, controlled chronic wound environment that ensures a continuous fresh supply of therapeutic solutions to the wound. DermaStream is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound life cycle from debridement, through regeneration to wound closure. DermaStream was designed for use in hospitals, clinics and for home care.
EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients by shortening healing time and reducing treatment costs. For more information, visit www.dermastream.com
Contact
Nicky Colomb
Virginia BioTechnology Research Park
Phone: (804) 828-6884
E-mail: ncolomb@vabiotech.com
Web site: www.vabiotech.com
Boaz Gruener
Director of Marketing and Business Development
Phone: +972-54-4563608
E-mail: boazg@enzysurge.com
|
